ARTICLE | Product Development
Zymeworks showcases >45% confirmed ORRs for anti-HER2 bispecific in biliary, gastroesophageal cancers
January 16, 2021 2:21 AM UTC
Phase I data Zymeworks presented Friday for its bispecific anti-HER2 mAb back its ongoing and pending pivotal trials in biliary tract and gastroesophageal cancers, respectively.
In an oral presentation at the American Society of Clinical Oncology (ASCO) gastrointestinal cancers symposium, Zymeworks Inc. (TSX:ZYME; NYSE:ZYME) reported Phase I data showing zanidatamab led to a confirmed objective response rate (ORR) of 47% in 15 Herceptin trastuzumab-naïve biliary tract cancer (BTC) patients, and an overall ORR of 40% in 20 patients. The candidate also led to an overall disease control rate (DCR) of 65% and a median duration of response (DOR) of 7.4 months...
BCIQ Company Profiles